A new pharmaceutical product Lemtrada (INN Alemtuzumab) developed by Sanofi Genzyme to treat multiple sclerosis - an autoimmune disease of the nervous system that mainly affects young people between the ages of 20 and 40 got the Marketing Authorization from the State Expert Center of the Ministry of Health of Ukraine.
Lemtrada is approved in more than 70 countries of the world. Due to the mode of action, the drug can modify the disease progression and is administered by intravenous infusion as two main treatment courses followed if needed by third and fourth rounds of treatment courses.
Therefore, the registration in Ukraine of Lemtrada offers new opportunities to treat the patients with relapsing-remitting multiple sclerosis.
The new drug to treat multiple sclerosis is not only highly effective therapy but also a drug that may change the life quality of patients with MS and help them to fight this heavy disease.
Lemtrada will be available in the market of Ukraine in October 2019.